Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 6—June 2005

Research

Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance

David J. Farrell*Comments to Author , Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Author affiliations: *G.R. Micro Ltd, London, United Kingdom; †Mount Sinai School of Medicine, New York, New York, USA; ‡Clinical Microbiology Institute, Wilsonville, Oregon, USA; §sanofi-aventis, Bridgewater, New Jersey, USA; ¶Emory University, Atlanta, Georgia, USA; #University of the Witwatersrand, Johannesburg, South Africa

Main Article

Table 3

Proportion of erythromycin-resistant Streptococcus pneumoniae isolates collected from years 1 to 3 of the PROTEKT US study that exhibit the dual mef(A)+erm(B) genotype according to source of isolate*

Source of isolate No. erm(B)+mef(A)–positive/no. erythromycin-resistant (%)
Year 1 Year 2 Year 3
BAL 35/346 (10.1) 47/349 (13.5) 74/426 (17.4)
Blood 24/805 (3.0) 31/568 (5.5) 37/641 (5.8)
CSF 1/2 (50.0)
Ear 67/420 (16.0) 48/246 (19.5) 107/354 (30.1)
Eye 3/16 (18.8) 11/120 (9.2) 2/7 (28.6)
MEF 2/34 (5.9) 6/29 (20.7) 14/40 (35.0)
NAP 34/246 (13.8) 43/242 (17.8) 51/235 (21.7)
Sinus 18/162 (11.1) 15/159 (9.4) 36/180 (20.0)
Sputum 117/1,056 (11.1) 129/1,050 (12.3) 199/1,294 (15.4)
Throat 1/15 (6.7) 1/8 (12.5)
Not specified 3/33 (9.1) 3/20 (15.0)
Total 304/3,133 (9.7) 335/2,793 (12.0) 520/3,177 (16.4)

*BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; MEF, middle-ear fluid; NAP, nasopharyngeal swab or aspirate; –, no isolates collected.

Main Article

TOP